Nymox Pharmaceutical Corporation NYMXF
OTC PK
| 12/31/2024 | 09/30/2024 | 12/31/2023 | |||
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | ||
| Total Other Revenue | -- | -- | -- | ||
| Total Revenue | -- | -- | -- | ||
| Cost of Revenue | -- | -- | -- | ||
| Gross Profit | -- | -- | -- | ||
| SG&A Expenses | -94.20% | -59.77% | 390.47% | ||
| Depreciation & Amortization | -- | -- | -- | ||
| Other Operating Expenses | -- | -- | -- | ||
| Total Operating Expenses | -83.75% | -35.60% | 387.66% | ||
| Operating Income | 83.75% | 35.60% | -387.66% | ||
| Income Before Tax | 83.86% | 30.89% | -296.64% | ||
| Income Tax Expenses | -- | -- | -- | ||
| Earnings from Continuing Operations | 83.86% | 30.89% | -296.64% | ||
| Earnings from Discontinued Operations | -- | -- | -- | ||
| Extraordinary Item & Accounting Change | -- | -- | -- | ||
| Minority Interest in Earnings | -- | -- | -- | ||
| Net Income | 83.86% | 30.89% | -296.64% | ||
| EBIT | 83.75% | 35.60% | -387.66% | ||
| EBITDA | 83.74% | 35.44% | -386.97% | ||
| EPS Basic | 84.28% | 31.25% | -288.59% | ||
| Normalized Basic EPS | 82.83% | 31.43% | -256.99% | ||
| EPS Diluted | 84.28% | 10.71% | -288.59% | ||
| Normalized Diluted EPS | 82.83% | 31.43% | -256.99% | ||
| Average Basic Shares Outstanding | 2.48% | 1.50% | 2.26% | ||
| Average Diluted Shares Outstanding | 2.48% | 1.50% | 2.26% | ||
| Dividend Per Share | -- | -- | -- | ||
| Payout Ratio | -- | -- | -- | ||